Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form1449A-PTO 10/22,664 **Application Number** 31 July 2003 Int'l Filing Date INFORMATION DISCLOSURE First Named Inventor Heinz-Josef LENZ STATEMENT BY APPLICANT **Art Unit** Not Yet Assigned **Examiner Name Not Yet Assigned** (use as many sheets as necessary) Sheet of **Attorney Docket Number** US7000732001

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,				
Initials*	No. <sup>1</sup>	Number – Kind Code <sup>2</sup> (if known)	MM-DD-YY	Application of Cited Document	Where Relevant Passages or Relevant Figures Appear				
/CM/	1	US-5,705,336	01-06-98	Reed et al.					
	2	US-6,716,581 B2	04-06-04	Lenz et al.					
V	3	US-2004/0067519 A1	04-08-04	Lenz et al.					
		US-							
		US∙		·					
		US-		·					
		US-			•				
		US-	·						
		US-							
		US-							

Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	1
Initials*	No.1	Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	MM-DD-YY	Application of Cited	Where Relevant Passages	
				Document	or Relevant Figures Appear	
/CM/	4	WO 01/36686 A2 & A3	05-25-01	University of Southern		Π
701417				California		<u> </u>
	5	WO 01/75175 A2, R5 & A3	10-11-01	University of Southern		Γ
ملد	L			California		
V	6	WO 2004/011625 A2 & A3	02-05-04	University of Southern		
				California		<u> </u>

Examiner's		 Data	· · · · · · · · · · · · · · · · · · ·	<del></del>
Signature	/Carla Myers/	 Date Considered	10/30/2007	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Inter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known		
Substitute for form 1449B-PTO					Application Number	10/522,664	
	INFORM	ΛΑΤΙΩΝ	DISCLOS	IIRE	Int'l Filing Date	31 July 2003	
					First Named Inventor	Heinz-Josef LENZ	
	SIAIE	MENIB	Y APPLIC	ANI	Art Unit	Not Yet Assigned	
(use as many sheets as necessary)					Examiner Name	Not Yet Assigned	
	Sheet	1	of	3	Attorney Docket Number	US7000732001	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	1
initials*	No.1	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	
/CM/		ABDEL-RAHMAN, S. et al. "Polymorphisms in DNA Repair Gene XRCC1 Increases the Risk of Colorectal Cancer in Egypt" <i>Proceedings of the American Association for Cancer Research</i> (March 2000) 41:595, No. 3791	
	2	BOARD, P.G. et al. "Isolation of a cDNA clone and localization of the humnan glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13-14" <i>Ann. Hum. Genet.</i> (1989) <b>53</b> :205-213	
-35	3	CALDECOTT, K.W. et al. "XRCC1, A Central Regulator of Single Strand Break Repair and Base Excision Repair" Proceedings of the American Association for Cancer Research (March 2000) 41:891, No. 526	
	4	DUELL, E.J. et al. "Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells" Carcinogenesis (May 2000) 21(5):965-971	
	5	DIVINE, K.K. et al. "The XRCC1 399 GLN Polymorphism: Potential Association with Lung Adenocarcinoma" <i>Proceedings of the American Association for Cancer Research</i> (March 2000) 41:591, No. 3762	
	6	EDLER, D. et al. "Thymidylate Synthase Expression: An Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-free and Overall Survival in Rectal Cancer" Clinical Cancer Research (April 2000) 6:1378-1384	
	7	HALPERN, J. "Maximally Selected Chi Square Statistics for Small Samples" <i>Biometrics</i> (December 1982) 38:1017-1023	
	8	HARRIES, L.W. et al. "Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer" Carcinogenesis (1997) 18(4):641-644	
	9	HEIDELBERGER, C. et al. "Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds" Nature (March 30, 1957) 179:663-666	
	10	HORIE, N. et al. "Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase" Cell Structure and Function (1995) 20:191-197	
$\overline{\Psi}$	11	HORIKOSHI, T. et al. "Quantitation of Thymidylate Synthase, Dihydrofolate Reductase, and DT- Diaphorase Gene Expression in Human Tumors Using the Polymerase Chain Reaction" Cancer Res. (Jan. 1, 1992) 52:108-116	

Examiner's Signature	/Carla Myers/	Date Considered	10/30/2007
			I

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*\*Applicant's unique citation designation number (optional). \*\*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 14498-PTO 10/522,664 **Application Number** Int'l Filing Date 31 July 2003 INFORMATION DISCLOSURE First Named Inventor Heinz-Josef LENZ STATEMENT BY APPLICANT Art Unit Not Yet Assigned **Not Yet Assigned** (use as many sheets as necessary) **Examiner Name** Sheet: 2 3 **Attorney Docket Number** US7000732001

		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite No.1  /CM/ 12		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published					
		HOWIE, A.F. et al. "Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues" Carcinogenesis (1990) 11(3):451-458	·				
	13	HU, J.J. et al. "Genetic Polymorphism of DNA Repair in Human Prostate Cancer Risk" Proceedings of the American Association for Cancer Research (March 2000) 41:596, No. 3798					
	. 14	ISHIKAWA, Y. et al. "Dihydropyrimidine Dehydrogenase Activity and Messenger RNA Level May Be Related to the Antitumor Effect of 5-Fluorouracil on Human Tumor Xenografts in Nude Mice" Clin. Cancer Res. (April 1999) 5:883-889					
	15	LEICHMAN, C.G. et al. "Quantitation of Intratumoral Thymidylate Synthase Expression Predicts for Disseminated Colorectal Cancer Response and Resistance to Protracted-Infusion Fluorouracil and Weekly Leucovorin" J. Clinical Oncology (Oct. 1997) 15(10):3223-3229					
	16	MANNERVIK, B. "The Isoenzymes of Glutathione Transferase" Adv. Enzymol. (1985) 57:357-417					
	17	MILLER, R. and D. SIEGMUND "Maximally Selected Chi Square Statistics" <i>Biometrics</i> (Dec. 1982) 38:1011-1016					
	18	MOSCOW, J.A. et al. "Expression of Anionic Glutathione-S-transferase and P-Glycoprotein Genes in Human Tissues and Tumors" Cancer Res. (March 15, 1989) 49:1422-1428					
	19	NISHIMURA, T. et al. "Association between expression of glutathione-associated enzymes and reponse to platinum-based chemotherapy in head and neck cancer" Chemico-Biological Interactions (1998) 111-112:187-198					
	20	PETERS, W.H.M. et al. "Expression of Drug-Metabolizing Enzymes and P-170 Glycoprotein in Colorectal Carcinoma and Normal Mucosa" Gastroenterology (Aug. 1992) 103:448-455					
	21	SALONGA, D. et al. "Colorectal Tumors Responding to 5-Fluorouracil Have Low Gene Expression Levels of Dihydropyrimidine Dehydrogenase, Thymidylate Synthase, and Thymidine Phosphorylase" Clin. Cancer Res. (April 2000) 6:1322-1327					
	22	SINGH, S.V. et al. "Differential expression of glutathione S-transferase, glutathione peroxidase, and glutathione reductase in normal and malignant human breast tissues" Cancer Letters (1990) 51:43-48					
	23	STERN, M.C. et al. "DNA Repair Gene XRCC1 Polymorphisms, Smoking and Bladder Cancer Risk"  Proceedings of the American Association for Cancer Research (March 2000) 41:592, No. 3771					
V	24	SWEENEY, C. et al. "Association between Survival after Treatment for Breast Cancer and Glutathione S-Transferase P1 Ile <sup>105</sup> Val Polymorphism" Cancer Res. (Oct. 15, 2000) 60:5621-5624					

Examiner's Signature	/Carla Myers/	Date Considered	10/30/2007

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B-PTO 10/522,664 **Application Number** 31 July 2003 Int'l Filing Date INFORMATION DISCLOSURE **First Named Inventor Heinz-Josef LENZ** STATEMENT BY APPLICANT **Not Yet Assigned Art Unit Not Yet Assigned Examiner Name** (use as many sheets as necessary) US7000732001 Sheet 3 **Attorney Docket Number** of

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T
Initials*	No. <sup>3</sup>	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	
/CM/	25	TERRIER, P. et al. "An Immunohistochemical Study of Pi Class Glutathione S-Transferase Expression in Normal Human Tissue" Am. J. Pathol. (Oct. 1990) 137(4):845-853	
1	26	TSUCHIDA. S. and K. SATO "Glutathione Transferases and Cancer" Rev. Biochem. Mol. Biol. (1992) 27(4,5):337-384	
	27	van LIESHOUT, E.M.M. "Polymorphic Expression of the Glutathione S-Transferase P1 Gene and Its Susceptibility to Barrett's Esophagus and Esophageal Carcinoma" Cancer Res. (Feb. 1, 1999) 59(3):586-589	
	28	WATSON, M.A. et al. "Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution Carcinogenesis (1998) 19(2):275-280	
	29	WEI, X. et al. "Molecular Basis of the Human Dihydropyrimidine Dehydrogaenase Deficiency and 5- Fluorouracil Toxicity" J. Clinical Investigations (August 1996) 98(3):610-615	
\/	30	ZIMNIAK, P. et al. "Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties" Eur. J. Biochem. (1994) 224:893-899	
V	31	International Search Report for PCT/US2003/024065 dated Sept. 27, 2004	
			F
			F
			L
			L

Examiner's Signature	/Carla Myers/	Date Considered		10/30/2007
			THE RESERVE OF THE PARTY OF THE	the same of the same of the same of

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Considered, Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is unique citation designation is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number

	Substitute f	or form 1449B	/PTO	Complete if Known			
	INFORMAT	ION DISCLO	SURE	Application Number	10/522,664		
STATEMENT BY APPLICANT			ICANT	Filing Date	July 31, 2003		
	Date Submitted: January 11, 2006			First Named Inventor	Heinz-Josef Lenz		
	Date Submitte	o. January	11, 2000	Group Art Unit	Not Yet Assigned		
	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	064189-0604		

U.S. PATENT DOCUMENTS							
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Cite Initials* No.	No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
/CM/	1	6,716,581	B1	Lenz et al.	4/6/04		
			·				
			<del></del>				
· -							
				***			
		· · · ·	<del></del>			.,, <u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	
					· .		
			·				
	·						
				<u> </u>		· .	

	·	U.S. Patent Ap	plication	. PATENT APPLICATION DOCL	Filing Date of	Pages, Columns, Lines, Where Relevant
Examiner Initials* Cite		Docume Serial Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
/CM/	2	2004/0067519	A1	Lenz	08/05/03	
			_ :			<u> </u>
		-				
				·		

Examiner   Date   Carla Myers/   Considered   10/30/2007			P * 1	
	/Carla Myers/		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (MIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup>Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form	1449B	PTO		Complete if Known
	INFORMATION DIS	SCLO	SURE	Application Number	10/522,664
	STATEMENT BY	APPLI	CANT	Filing Date	July 31, 2003
	Date Submitted: Jan		1 2006	First Named Inventor	Heinz-Josef Lenz
	Date Submitted, Jan	ualy	1, 2000	Group Art Unit	Not Yet Assigned
	(use as many sheets	as ne	cessary)	Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	064189-0604

				F	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. <sup>1</sup>	For Office <sup>3</sup>	reign Patent D Number <sup>4</sup>	ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>€</sup>
/CM/	3	wo	04/037852	A2	University of Medicine and Dentistry of New Jersey; University of Southern California	May 6, 2004		
			_		:	7. 1 1 2 3-419 161 1 1 1 1 1 1 1 1 1 1 1 1 1		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁰
/CM/	4	IACOPETTA, B. et al. "A Polymorphism in the Enhancer Region of the Thymidylate Synthase Promoter Influences the Survival of Colorectal Cancer Patients Treated with 5-Fluorouracil" British Journal of Cancer, London, GB" (September 14, 2001) 85(6):827-830	
	5	LENZ, HEINZ-JOSEF et al. "A 6 base-pair deletion in the 3 UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: A possible candidate gene for colorectal cancer risk" Proceedings of the American Association for Cancer Research Annual Meeting (March 2002) 43:660	
	6	PARK, DAVID J. et al. "Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer" <i>International Journal of Colorectal Disease</i> (January 2002) 17(1):46-49	
	7	PULLARKAT, S. et al. "Thymidylate Synthase Gene Polymorphism Determines Response and Toxicity of 5-FU Chemotherapy" <i>Pharmacogenomics Journal</i> (2001) 1(1):65-70	
	8	SHIROTA, Y. et al. "ERCC1 and Thymidylate Synthase MRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy" Journal of clinical Oncology (December 1, 2001) 19(23):4298-4304	
	9	Ulrich et al. "Searching Expressed Sequence Tag Databases: Discovery and Confirmation of a Common Polymorphism in the <i>Thymidylate Synthase</i> Gene" Cancer Epidemiology, Biomarkers & Prevention (2000) 9:1381-1385	
	10	Villafranca et al. "Polymorphisms of the Repeated sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer" (2001) Journal of Clinical Oncology 19(6):1779-1786	
V	11	European Search Report for EP 03 77 2163 dated October 4, 2005	

		and the second	Alexander of the state of the s
Examiner Signature	/Carla Myers/	Date Considered	10/30/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

number. '

Shee

Under the Paper of Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control GTRA

DEMAN	Substitute for form 1	449B/	PTO		Complete if Known	
	NFORMATION DIS	CLO	SURE	Application Number	10/522,664	
5	STATEMENT BY A	PPLI	CANT	Filing Date	7/31/2003	
-	Date Submitted: Ma	rob 2	2006	First Named Inventor	Heinz-Josef Lenz	
L	date Submitted. Ma	iicii 3	, 2000	Group Art Unit	1634	
(us	e as many sheets	as ne	cessary)	Examiner Name	Carla J. Myers	
t	1	of	2	Attorney Docket Number	064189-0604	

			U.S. PATENT DOCUMENTS		
 	U.S. Patent Document		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (# known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
 					<u> </u>
		_			
 		<del></del>			
 					·
 		<del>- </del> -			
 	•				
 <del>-  </del>					
					·

			U.S	. PATENT APPLICATION DOCU	MENTS	
Examiner Initials*	Cite	U.S. Patent Application  Document		Name of Colonia and April 1	Filing Date of	Pages, Columns, Lines, Where Relevant
	No.1	Serial Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
					to a series from the first of the series of the series of the	De la chier de la companya de la com

				FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	For Office <sup>3</sup>	eign Patent D Number <sup>4</sup>	Oocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>®</sup>
							,	
								<u> </u>

	A STATE OF THE RESIDENCE OF THE PARTY OF THE	the state of the s	
Examiner Signature	/Carla Myers/	Date Considered	10/30/2007

\*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through diation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRADES Stitute for form 1449B/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/522,664 STATEMENT BY APPLICANT Filing Date 7/31/2003 Heinz-Josef Lenz First Named Inventor Date Submitted: March 3, 2006 **Group Art Unit** 1634 (use as many sheets as necessary) **Examiner Name** Carla J. Myers 2 Sheet Attorney Docket Number 064189-0604

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	1 <sub>e</sub>
/CM/	1	Kuniyasu et al. "Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer" American Journal of Pathology (Nov. 2000) 157(5):1523-1535	
/CM/	2	Fox et al. "Angiogenesis in normal tissue adjacent to colon cancer" Journal of Surgical Oncology (Dec. 1998) 69(4):230-234	
/CM/	3	Liotta et al. "The microenvironment of the tumour-host interface" Nature (May 2001) 411(6835):375-379	
/CM/	4	European Search Report for EP 03772163.6 dated 2/3/06	
/CM/	5	Promega Catalog (1997) page 78	
,			

	A H C II A C S - C OF STATE I S IN A A S A SHE IN A S		IN the parties about the target party and a second transfer of the second transfer of the second
Examiner Signature	/Carla Myers/	Date Considered	10/30/2007
	والمنافذ		The state of the s

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through dilation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAR 0 6 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO		Complete if Known		
% INFORMATION DISCLOSURE	Application Number	10/522,664		
TATEMENT BY APPLICANT	Filing Date	7/31/2003		
Rate Submitted: January 29, 2007	First Named Inventor	Heinz-Josef Lenz		
a	Art Unit	1634		
(Asse as many sheets as necessary)	Examiner Name	Carla J. Myers		
1 of 1	Attorney Docket Number	064189-0604		

U.S. PATENT DOCUMENTS					
Examiner Cite No.1	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
_/CM/	1	5,985,561	11/16/1999	Kimberly et al.	
	2	2005/0064417	03/24/2005	Watier et al.	
V	3	2006/0008825	01/12/2006	Levy et al.	
					<u> </u>
				the state of the s	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code <sup>2</sup> (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Ciled Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
					20. 130. 0.11. 111. 111.	
						+

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>®</sup>			
		the state of the s				

	The Committee of the Co	The state of the s	THE THE TRACE STREET,
Examiner Signature	/Carla Myers/	Date Considered	10/30/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.